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Chapter 1: Introduction 
 
1.0 Research Motivation 
Maintaining drug concentrations within therapeutic range has long been a sought after goal in the 
pharmaceutical industry. This maintenance is embodied in a zero-order release profile, or constant 
(controlled) release. This allows for a minimization of side effects while constantly maximizing 
efficacy. Traditional drugs taken orally are plagued by a variety of factors that make a constant 
concentration nearly impossible, such as degradation in the digestive system, variability in patient 
metabolisms, and nonspecific targeting of a dose. Depot injections of drug allow for localized 
delivery, lower doses, and can ameliorate some of these variable factors, but are, on their own, still 
unable to address the need for a flat concentration profile. Long-acting formulations are becoming 
increasingly prevalent as a tool to address this need, with the added benefits of addressing patient 
noncompliance and simplifying treatment regimens. Long-acting formulations are most useful for 
the treatment of chronic conditions (e.g. heart conditions, cancer), conditions that require constant 
concentration in the body (e.g. vaccines, antibiotics), and conditions that affect patient compliance 
(e.g. schizophrenia, bipolar disorder). Many of the formulations that are currently on the market 
lengthen the lifetime of a dose, but few also address the issue of a consistent dosing. 
 
Improving long-acting parenteral drug formulations allows for improved efficacy, decreased 
side effects, patient compliance, and reduced cost of care, making it an invaluable tool in the 
optimization of drug regimens.  
 
In this paper, the application of a cross-flow membrane emulsification technique for the 
manufacture of combinations of monodisperse poly(lactic-co-glycolic acid) (PLGA) microspheres 
with haloperidol, a drug primarily used for the treatment of schizophrenia, for a zero-order, 
controlled release depot injection is explored. The use of a model drug allows for the demonstration 
of the optimization technique applicable to a wide range of therapeutic substances, both for the 
production process and downstream processing of the microparticles. A detailed description of the 
reagent, device, and processing unit specifications is discussed, and followed by an economic 
feasibility analysis of the platform technology and the impact of such a platform on the chronic 
disease management markets.  
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The technical specifications of the process will be tailored towards the production of 
500,000 month-long patient doses of haloperidol-PLGA microspheres in the first year of 
production. Production occurs on a compressed 90 day schedule, which allows the plant to dedicate 
the remaining 75% of its operating year towards new products and leaving room for additional 
capacity. 500,000 doses accounts for approximately 42,000 patients treated per year, assuming a full-
year regimen, which is approximately 2% of the U.S. schizophrenia market. Haloperidol itself 
currently accounts for 0.2% of the total U.S. schizophrenia market, but with the extended release 
and controlled release features of the polymer microspheres, this share is expected to increase to 4% 
within a six year window.  
 
While sales of haloperidol are limited due to the increased genericization of other drugs with 
the same indication, the potential behind the XME technology as a platform for drug development 
has much greater potential. The populations and drugs that may benefits from the additional 
features of the XME platform include those drugs with dangerous side effect profiles 
(chemotherapy), diseases with poor patient compliance (mental illnesses), chronic diseases that 
require consistent treatment (diabetes, heart disease, oncology), and indications that have a 
concentration at which optimal performance is achieved (antibiotics, vaccines). The potential 
revenue from additional development in these areas is vast, and is an additional consideration to the 



















Project Name Microfluidic Production of Depo-haloperidol with a Controlled Release 
Profile  
Project Champions Dr. John C. Crocker, U. Penn;  Robert Meyer, Merck & Co. 
Project Leaders Gregory Cordina, Abby Lee, William Mulhearn, Gurnimrat Sidhu 
Specific Goals Develop an optimized cross-flow membrane emulsification (XME) 
process design delivering Depo-haloperidol droplets of an optimal 
particle size distribution correlating to constant drug release profiles 
Project Scope In-Scope: 
• XME-based process using PLA/PLGA matrices 
• Produces spheres at most 100!m in size (18 gauge hypodermic 
needle – maximum blood entrainment size) 
• Continuous or batch-continuous processes 
• Application of process to production of other drugs 
Out-of-Scope: 
• Other methods of microfluidic production 
• Non-continuous production design 
Deliverables • Microfluidic drop formation device design 
• Modeled drug release profile of desired particle-size distribution 
• Technical feasibility assessment for commercially relevant scale of 
product (500,000 patient doses/year) 
• Capability assessment for a pharmaceutical manufacturing facility 
based on quality regulations and capital and operating costs 
Timeline Project feasibility and design reports to take place over the course of 


















1.2  Technological Readiness Assessments 
 
 





































1.3  Market and Competitive Analysis 
The total prevalence of schizophrenia globally is 24 million. Of this 24 million, only 4.6 million are 
diagnosed and treated, which accounts for approximately 19.1% of the total population. 
Schizophrenia drugs comprise a $5.7 billion market.  
 
There are two drug classes that treat schizophrenia: typical antipsychotics and atypical 
antipsychotics. Typical antipsychotics were the first generation of drugs developed to treat mental 
disorders. The class has since been overtaken by atypical antipsychotics, which were thought to have 
improved side effect profiles and higher efficacy. Haloperidol, the model drug used in this paper, is a 
typical antipsychotic. Its comparatively poor side effect profile led to it being overtaken by drugs in 
the atypical sector; however, recent clinical studies indicating that most side effects experienced with 
haloperidol were a direct result of the patient taking too much or too little of the drug.  
 
The maintenance of an optimized concentration has been a long sought after goal in the 
pharmaceutical industry, and the benefits of such a dosing methodology are not limited to 
haloperidol alone. A drug delivery technology involving drug embedded within polymer 
microspheres is one way to begin the solution. Polymer microspheres have predictable drug release 
profiles that are dependent on size, and different sizes can be combined to deliver a constant 
optimized concentration, referred to as a zero-order release profile. The second advantage to these 
polymer microspheres is their ability to extend the lifetime of a single dose, a fringe benefit of their 
release profiles.  
 
The manufacture of these microspheres must be precise to ensure a zero-order release 
profile. This paper explores the ability of cross-flow membrane emulsification (XME) to produce 
monodisperse polymer microspheres for drug delivery.  
 
Combining haloperidol with XME technology to produce a controlled, extended release 
formulation would be a new generation of antipsychotics. Currently, there are several extended 
release formulations on the market. The products that would compete with our product are the oil-
based, esterified versions of typical antipsychotics that allow for more convenient dose schedules. In 
particular, our economic analysis in Chapter 7 focuses on haloperidol decanoate, the extended 
release formulation of haloperidol. These esterified extended release formulations suffer from one 
7 
main flaw: their inability to deliver a zero-order release profile. These formulations are generally only 
used for mild cases of schizophrenia, due to the danger inherent in the inconsistency of drug levels, 
which lead to suboptimal clinical outcomes.  
 
Other extended release formulations on the market include Seroquel XR®, an extended 
release formulation of quetiapine, a drug used to treat schizophrenia, bipolar disorder, mania, and 
depression. Seroquel XR® does not have a controlled release feature, and is more commonly used in 
indications outside of schizophrenia. It is a once-daily tablet, as compared to haloperidol dosing that 
is generally twice-daily. The finalized product specifications of the haloperidol controlled release 
product are for a single dose per month, which would improve the dosing convenience dramatically.  
 
Outside of the typical sector esterified formulations and Seroquel XR®, the haloperidol 
controlled release profile does not have any comparable competitors, and is expected to overtake 
market share from both the typical and atypical sectors. The expected market share for the product 
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4.2 Channel Operation and Throughput 
 
A cross-flow membrane emulsification channel has nine independent operating parameters: 
interfacial tension, continuous phase viscosity, dispersed phase viscosity, continuous phase density, 
dispersed phase density, continuous phase superficial velocity, dispersed phase flow rate per pore, 
channel height, and pore diameter. These operating variables interact to produce secondary effects, 
like shear rate at the channel floor and drag coefficient at a forming droplet, but we cannot 
manipulate these secondary effects directly. In Chapter 4.1, we made some design selections based 
on a physical understanding of our system and locked in eight of these independent parameters. For 
a given target dry diameter for a PLGA sphere, all operating parameters except continuous phase 
flow rate are defined and unchangeable. To review this selection, Table 4.1 lists the specified values 
for each parameter. 
 
  Operating Parameter Value Notes 
        
1 Interfacial Tension 0.008 N/m   
2 Dispersed Phase Viscosity 0.006 Pa-s 10 vol% solids (PLGA and haloperidol) 
3 Dispersed Phase Density 1.32 g/mL  10 vol% solids (PLGA and haloperidol) 
4 Continuous Phase Viscosity 0.0014 Pa-s 1 wt% PVA 1.27 wt% DCM in water 
5 Continuous Phase Density 1.007 g/mL  1 wt% PVA 1.27 wt% DCM in water 
6 Pore Diameter Dwet / 2.4 Limited by Rayleigh instability 
7 Dispersed Phase Flow Rate (Per Pore) (0.5 D03 ! / "DP)1/2 Limited by the Weber number 
8 Channel Height 0.5 mm   
9 Continuous Phase Superficial Velocity [unspecified] This parameter is left free 
 
Table 4.1. Summary of operating parameter specifications. 
 
 Dwet represents the diameter of an emulsified droplet prior to drying, which is set by the 
target dry particle diameter by Equation 2.1 and our choice of a dispersed phase concentration of 
10% solid materials (PLGA and haloperidol) by volume. D0 is the pore diameter. ! is the interfacial 
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0.001745 u Ddry( )
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                                                                                                                                   (Equation 4.12) 
 
 This equation has been set up with the appropriate conversion factors so that Ddry has units 
of micrometers and u has units of meters per second. The input parameters are all specified in Table 
4.1. For each choice of dry diameter from Table 3.1, we substitute the dry diameter into Equation 
2.19 and use a computer algebra system to solve for continuous phase flow rate u. These tabulated 
flow velocities are reported in Table 4.4. The required flow velocity is independent of channel width 
(as long as the channel width is much greater than the height). We use a channel width of 10 cm as a 
test case, and report the corresponding continuous phase volumetric flow rate per channel for each 
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Stream Unit-out Unit-in   Component Flow rate   
FEED 1 S-1 Small-particle 
channel array 
 total 2610.144 kg/hr 
 CP Storage Tank  DI Water 2550.894  
    PVA 26.101  
    DCM 33.149  
FEED 2 M-2 Small-particle 
channel array 
  total 8.791 kg/hr 
 DP Mixing/Storage Tank  PLGA 0.731  
    Haloperidol 0.087  
    DCM 7.973  
FEED 3 S-1 Large-particle 
channel array 
  total 163.134 kg/hr 
 CP Storage Tank  DI Water 159.431  
    PVA 1.631  
    DCM 2.072  
FEED 4 M-2 Large-particle 
channel array 
  total 1.763 kg/hr 
 DP Mixing/Storage Tank  PLGA 0.147  
    Haloperidol 0.017  
    DCM 1.599  
OUTFLOW S Small-particle channel 
array 
T-1   total 57.731 kg/hr 
 CSTR - small particles  PLGA 0.731  
    Haloperidol 0.087  
    DI Water 47.829  
    PVA 0.489  
 *includes emulsified smaller particles  DCM* 8.595  
OUTFLOW L Large-particle channel 
array 
T-2   total 784.806 kg/hr 
 CSTR - large particles  PLGA 0.147  
    Haloperidol 0.017  
    DI Water 765.268  
    PVA 7.830  
 *includes emulsified larger particles  DCM* 11.544  
       
!"#$
!
Stream Unit-out Unit-in   Component Flow rate   
DIVERT 1 Large-particle channel 
array 
T-3   total 114.194 kg/hr 
 Surge Tank  DI Water 111.602  
    PVA 1.142  
    DCM 1.450  
DIVERT 2 Small-particle channel 
array 
T-3   total 1827.101 kg/hr 
 Surge Tank  DI Water 1785.626  
    PVA 18.271  
    DCM 23.204  
NACL 1 -- T-2   total 775.213 kg/hr 
  CSTR - large particles  0.5 M NaCl 775.213  
NACL 2 -- T-1   total 48.451 kg/hr 
  CSTR - small particles  0.5 M NaCl 48.451  
WATER 1 -- T-2   total 193.803 kg/30 min 
  CSTR - large particles  DI Water 193.803  
WATER 2 -- T-1   total 12.113 kg/30 min 
  CSTR - small particles  DI Water 12.113  
SOAK 1 -- T-2   total 387.606 kg/hr 
  CSTR - large particles  DI Water 387.606  
SOAK 2 -- T-1   total 24.225 kg/hr 
  CSTR - small particles  DI Water 24.225  
DIVERT 3 T-2 T-3   total 1067.386 kg/3 hrs 
 CSTR - large particles Surge Tank  DI Water 288.840  
    PVA 1.468  
    DCM 1.865  
    0.5 M NaCl 775.213  
DIVERT 4 T-1 T-3   total 4723.219 kg/3 hrs 
 CSTR - small particles Surge Tank  DI Water 4621.443  
    PVA 23.491  
    DCM 29.834  
    0.5 M NaCl 48.451  
DIVERT 5 T-2 T-5   total 387.609 kg/hr 
 CSTR - large particles   DI Water 387.606  
    Haloperidol 0.002  
DIVERT 6 T-1 T-5   total 24.238 kg/hr 
 CSTR - small particles   DI Water 24.225  
    Haloperidol 0.012  
       
       
       
!"#$
!
Stream Unit-out Unit-in   Component Flow rate   
CP-DIST T-4 D-1   total 15216.178 kg/hr 
 Storage Tank Distillation Column  DI Water 9225.568  
    PVA 87.632  
    DCM 5902.978  
DRY L T-2 F-1   total 0.510 kg/3 hrs 
 CSTR - large particles Freeze-dry  DI Water residual  
    PLGA 0.433  
    PVA 0.032  
    Haloperidol 0.045  
DRY S T-1 F-1   total 2.542 kg/3 hrs 
 CSTR - small particles Freeze-dry  DI Water residual  
    PVA 0.159  
    PLGA 2.160  
    Haloperidol 0.223  
PRODUCT-L F-1 A-1   total 2.039 kg/12 hrs 
    PVA 0.127  
    PLGA 1.733  
    Haloperidol 0.179  
PRODUCT-S F-1 A-1   total 10.168 kg/12 hrs 
    PVA 0.634  
    PLGA 8.640  
        Haloperidol 0.894   
     
Total particles produced per 90 day process cycle     
Large (50 µm diameter)   367.039 kg  
Small (20 µm diameter)   1830.224 kg  
       
Total haloperidol encapsulated  193.114 kg  
      
Total haloperidol per dose   0.387 g  
Weight particles per standard dose   5.559 g  
Number doses produced   500,000 per process cycle 
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2018 Market Share, 2018f (%) 
Atypical Antipsychotics 18,347 14,896 -2.3 93.4% 
          
Seroquel 4,984 595 -21 3.7% 
Zyprexa 3,861 979 -14.1 6.1% 
Abilify 4,144 973 -14.9 6.1% 
Risperdal 850 473 -6.3 3.0% 
Risperdal Consta 1,088 384 -10.9 2.4% 
Geodon 1,054 138 -20.2 0.9% 
Invega 397 134 -11.4 0.8% 
Seroquel XR 267 204 -2.9 1.3% 
Atypical Generics 1,395 7,532 20.6 47.2% 




   
  
Typical Antipsychotics 668 1,049 5.1 6.6% 
          
Haloperidol 30 25 -1.9 0.2% 
Typical Generics 208 235 1.4 1.5% 




   
  
Total* 19,015 15,945 -0.1 100% 
  
  
  2009 - 96.5% (Atypical), 3.5% (Typical) 
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With Distillation Column $11,847,883 
 
  




   
  
Equipment 
   
  
  Bare Module Quantity 
Installation Cost per 
Unit 
Total Cost (All 
Units) 
Mixing Tank (M-1) 82200 2 $270,520.2 $705,440.40 
Mixing Tank (M-2) 2310 2 $7,602.2 $19,824.42 
Sanitary Pump (P-1) 2900 1 $9,543.9 $12,443.90 
Sanitary Pump (P-2) 3200 6 $10,531.2 $82,387.20 
Sanitary Pump (P-3) 2900 1 $9,543.9 $12,443.90 
Sanitary Pump (P-4) 2900 6 $9,543.9 $74,663.40 
Vacuum Tank with 
Diafiltration (T-1) 12100 6 $39,821.1 $311,526.60 
Vacuum Tank with 
Diafiltration (T-2) 35500 6 $116,830.5 $913,983.00 
Sanitary Pump (P-5) 2900 6 $9,543.9 $74,663.40 
Sanitary Pump (P-6) 3300 6 $10,860.3 $84,961.80 
Surge Tank (T-3) 55900 1 $183,966.9 $239,866.90 
Storage/Mixing Tank (T-4) 56800 1 $186,928.8 $243,728.80 
Storage Tank (T-5) 22500 1 $74,047.5 $96,547.50 
Pump (P-8) 2900 6 $9,543.9 $74,663.40 
Sanitary Pump (P-9) 3200 6 $10,531.2 $82,387.20 
Storage Tank (S-1) 17200 1 $56,605.2 $73,805.20 
Storage Tank (S-2) 20200 1 $66,478.2 $86,678.20 
Freeze-Dry (F-1) 99950 1 Inclusive $99,950.00 
Ampoule-Filling Unit (A-1) 1055000 1 Inclusive $1,055,000.00 
Sanitary Pump (UP-2) 1600 1 $5,265.6 $6,865.60 
Sanitary Pump (UP-1) 1600 1 $5,265.6 $6,865.60 
Distillation Column (D-1) 160500 1 $528,205.5 $688,705.50 
  
   
$5,047,402 
  
   
  
  Per Channel Quantity 
Total Cost (All 
Channels)   
Channels*  
                
$8,000  21 $168,000   
* no installation cost 
   
  
  
Cost per sq. 
ft. Quantity (sq. ft.) Total Cost   

















VARIABLE         
  
  
TOTAL   
With Distillation Column $60,152,327    
No Distillation Column $60,206,791    
  
   
  
Reagents 
   
  




DCM $0.50 $/kg 115532 $57,642  
Pharmaceutical-Grade Water $0.12 $/kg 8596372 $1,031,565  
PVA $0.71 $/kg 78522 $56,077  
PLGA $39,100.00 $/kg 1450 $56,696,828  
Haloperidol $10,676.00 $/kg 172 $1,832,971  
Sodium Chloride $0.13 $/kg 4209 $556.78 
  
   
$59,675,640  
  
   
  
Utilities 
   
  
  Cost 
  
  




   
  




   
  
Total Wastewater Treatment 




   
  
Total Treatment Cost $38,125  
  
  
Cost per kg Organic 0.33 
  
  




   
  
Transportation Cost $16,338  
  
  
Cost (% of Shipment Value) 1.50% 
  
  

















HR/Operational/SG&A     








Direct Wages and Benefits (24 
operators) $1,814,400.00 35 operator-hr 
Direct Salaries and Benefits $272,160.00 15% of DW&B 
Operating supplies and services $108,864.00 6% of DW&B 
Technical assistance to manufacturing $156,000.00 $52,000/(operator/shift)-year  










Wages and Benefits 
 
  
Solid-fluid handling process $533,154.74 4.5% of Ctdc 
Salaries and benefits $133,288.68 25% of MW&B 
Materials and services $533,154.74 100% of MW&B 










General plant overhead $47,317.48 7.1% of M&O-SW&B 
Mechanical department services $15,994.64 2.4% of M&O-SW&B 
Employee relations department $33,028.94 5.9% of M&O-SW&B 






















































































































































































































































































   
   
   
   
   
   
   











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































       
 
 $260   $280   $300   $320   $ 340   $360   $380  







































Reagent Prices*   
      * NaCl is neglected, due to the comparatively small amount used. 
   
       DCM 0.298927423 0.498927423 0.698927423 [$/kg] 
   NPV  $100,122,297  $100,075,294  $100,028,291  
    IRR  276.48% 275.79% 276.28% 
   
       Pharmaceutical-Grade 
Water 0.09 0.12 0.15 0.18 [$/kg] 
  NPV  $100,599,893  $100,075,294  $99,550,695  $99,026,096  
   IRR  277.52% 275.79% 275.23% 274.09% 
  
       PVA 0.514151856 0.714151856 0.914151856 1.114151856 [$/kg] 
  NPV  $100,106,768  $100,075,294  $100,043,820  $100,012,347  
   IRR  276.45% 275.79% 276.31% 276.24% 
  
       PLGA 39090 39100 39110 39120 39130 [$/kg] 
 NPV  $100,104,355  $100,075,294  $100,046,233  $100,017,172  $99,988,112  
  IRR  276.44% 275.79% 276.32% 276.25% 276.19% 
 
       Haloperidol 10656 10676 10696 10716 [$/kg] 
  NPV  $100,082,176  $100,075,294  $100,068,412  $100,061,530  




















    Atypical 15% 30% 45% 60% 75% 90% 
6 yr 13% 27% 40% 53% 67% 80% 
 
12% 23% 35% 47% 58% 70% 
 
10% 20% 30% 40% 50% 60% 
 
8% 17% 25% 33% 42% 50% 
 
7% 13% 20% 27% 33% 40% 
 
5% 10% 15% 20% 25% 30% 
       Typical 40% 57% 73% 90% 
  4 yr 40% 53% 67% 80% 
  
 
40% 50% 60% 70% 
  
 
40% 47% 53% 60% 
  
 
40% 43% 47% 50% 
  
 
40% 40% 40% 40% 
  
 
































Maximum Share Capture (linear ramp-up constant) 
      
          Additional Patients (from atypical market erosion) 
     
 
30 40 50 60 70 80 90 100 [%] 
 NPV  $90,184,484 $91,597,457 $93,010,430 $94,423,403 $95,836,375 $97,249,348 $98,662,321 $100,075,294 
  IRR  260.73% 262.98% 265.23% 267.47% 269.71% 271.93% 274.16% 275.79% 
 
          Haloperidol and Equivalents 
       
 
30 40 50 60 70 80 90 100 [%] 
 NPV  $38,031,812  $53,140,829 $60,963,240 $68,785,651 $76,608,061 $84,430,472 $92,252,883 $100,075,294 


























































 A Haloperidol and Equivalents Maximum Market Share         
  NPV 30 40 50 60 70 80 90 100 
Price  $           260  $12,845,885 $16,862,473 $20,879,061 $24,895,649 $28,912,237 $32,928,825 $36,945,413 $40,962,001 
   $           280  $20,926,644 $25,890,308 $30,853,971 $35,817,635 $40,781,299 $45,744,962 $50,708,626 $55,672,289 
   $           300  $29,007,404 $34,918,143 $40,828,882 $46,739,621 $52,650,360 $58,561,099 $64,471,838 $70,382,577 
   $           320  $37,088,164 $43,945,979 $50,803,793 $57,661,608 $64,519,422 $71,377,237 $78,235,051 $85,092,865 
   $           340  $38,031,812 $53,140,829 $60,963,240 $68,785,651 $76,608,061 $84,430,472 $92,252,883 $100,075,294 
   $           360  $53,249,684 $62,001,649 $70,753,615 $79,505,580 $88,257,546 $97,009,511 $105,761,476 $114,513,442 
   $           380  $61,330,444 $71,029,485 $80,728,526 $90,427,567 $100,126,607 $109,825,648 $119,524,689 $129,223,730 
  B   Haloperidol and Equivalents Maximum Market Share       
  IRR 30 40 50 60 70 80 90 100 
Price  $          260  96.10% 105.25% 113.29% 120.55% 127.20% 133.38% 139.18% 144.64% 
   $          280  129.14% 137.99% 145.97% 153.29% 160.09% 166.46% 172.48% 178.20% 
   $          300  161.57% 170.23% 178.17% 185.55% 192.46% 198.99% 205.19% 211.10% 
   $          320  193.66% 202.18% 210.09% 217.51% 224.51% 231.16% 237.51% 243.59% 
   $          340  176.02% 234.53% 242.42% 249.87% 256.94% 263.69% 270.16% 275.79% 
   $          360  257.24% 265.57% 273.44% 280.92% 288.05% 294.88% 301.45% 307.78% 














































































































The cross-flow membrane emulsification (XME) process was carried out on a laboratory scale in 
order to verify the accuracy of the emulsification equation (Equation 2.18, Chapter 2.3) and to 
confirm the ability of the process to generate monodisperse droplets. Before any attempts are made 
to scale-up the XME process to an industrial application, it is important to test the viability of the 
emulsification concept on a small scale. We run the XME process under a specified set of operating 
parameters, and compare the sizes of the generated droplets against the theoretical size predictions 
based on operating conditions. In general we find that the emulsification process generates a highly 
monodisperse size distribution, but the resulting droplets are significantly larger than the 
mathematical model predicts.  
 
Materials and Methods 
 
Continuous phase solutions are prepared by dissolving 97.73 wt% water, 1.27 wt% 
dichloromethane, and 1.00 wt% poly(vinyl alcohol). The solution is moderately heated for 30 
minutes to facilitate dissolution of the polymer, and then left to magnetically stir for 24 hours. 
Dispersed phase solutions are prepared by dissolving 0.098 wt% haloperidol, 0.860 wt% poly(lactic-
co-glycolic acid), and 99.042 wt% dichloromethane. This concentration is equivalent to 1% solid 
materials (haloperidol and PLGA) by volume. The solution is magnetically stirred for 24 hours 
before use.  
 
 The XME flow device consists of a narrow rectangular channel cut into an aluminum body. 
The dimensions of the channel are: height approximately 1 mm, width 6.4 mm, length in the 
direction of continuous phase flow 6 cm. At the base of the channel is a stainless steel membrane 
containing a single 100 µm diameter pore.  
 
 The flow rate of the continuous phase was set at 3 mL/s, for a superficial velocity through 
the channel of 0.469 m/s. Based on flow simulations performed in the computational fluid 
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mechanics suite in COMSOL Multiphysics, this flow rate in a rectangular channel of the given 
dimensions generates a shear rate of 2,500 s-1 at the channel floor. The flow rate of the dispersed 
phase was set at 2 mL/hr, giving a Weber number (Equation 2.9, Chapter 2.3) of 0.051, far below 
the transition to jetting behavior.  
 
 Product droplets were collected in a glass dish at the channel outlet. The sample was 
observed using a microscope, and visual measurements of particle diameter were recorded. The 
sample droplets are analyzed for monodispersity, and their average diameter is compared to the 
predictions of the emulsification model under these operating conditions. 
 
Results and Discussion 
 
Based on the supplied operating parameters, the theoretical size of emulsified droplets is 
predicted by Equation 4.11.  
 
                                                                       (Equation 4.11) 
 
Here Dwet is the diameter of an emulsified droplet, D0 is the pore diameter, Cd is the drag 
coefficient, OhCP is the continuous phase Ohnesorge number, and Ca is the capillary number. The 
drag coefficient, the Ohnesorge number, and the capillary number are defined in Chapter 3.3. Based 
on the supplies operating parameters, the model equation predicts that the outlet droplet size will be 
about 220 µm.  
 
Figure 8.1 shows a representative sample of the product droplets. The average droplet size is 
353 µm with a standard deviation of 97 µm. However, if we screen out extremely small “satellite” 
droplets, having diameter less than 200 µm, the average size becomes 390 µm with a standard 


















Figure 8.1. Sample photograph of emulsified droplets generated by the XME process. Included with a 500 
µm scale bar. 
 
 
 Excluding these satellite droplets, the monodispersity of the sample is quite good given our 
lack of experience with the XME equipment. The standard error in droplet size, ignoring satellites, is 
only 8% of the average diameter. The appearance of satellite droplets can be attributed to droplet 
disruption and break-up in the high-shear rate environment around sharp turns inside of the flow 
device. A pharmaceutical-grade device would be designed specifically to avoid these sharp turns.  
 
 Despite the high level of monodispersity we observe, the mathematical model predicts that 
the emulsified droplets should be significantly smaller than those collected. The average collected 
diameter, excluding satellites, is 390 µm, 77% larger than the expected 220 µm diameter droplets. 
This deviation can be largely attributed to small measurement errors on channel geometry. The 
predicted droplet size is especially sensitive to measurement accuracy on channel height. The height 
of the flow channel is approximately 1 mm, but we could only resolve the measurement to roughly 
±0.5 mm. A small error in the measured height, on the order of a few tenths of a millimeter, 
amounts to a large percent difference and would dramatically affect the actual shear rate at the 
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channel floor. If the height of the channel were actually 1.5 mm instead of the reported 1.0 mm, 
COMSOL simulations indicate that the experimental 3 mL/s continuous phase flow would actually 
generate a shear rate along the channel floor of 1,000 s-1, rather than the expected 2,500 s-1 for a 1.0 
mm height. With this new value for channel height, the predicted droplet size increases to 350 µm 





  This laboratory-scale test of the XME process supports the commercial value of the 
procedure. Even without long-term training and experience with the operating equipment, we were 
able to generate an emulsion of nearly-monodisperse droplets using similar materials to those 
detailed in the large-scale process design. Although the resulting droplets were unexpectedly large 
and we could not conclusively verify the emulsification model, the model’s size prediction remains 
plausible given expected measurement error on the small dimensions of the flow channel.  
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Chapter 9: Conclusions and Outlook 
 
The project thus described offers a comprehensive analysis of the product and process design 
components of time-release drug-loaded microspheres. The aim of this project was to manufacture a 
depot-release, zero-order haloperidol loaded poly(lactic-co-glycolic acid) (PLGA) microparticle in 
order to satisfy a need to overcome traditional dosing issues in the mental illness patients. These 
dosing issues include non-compliance (exacerbated by symptoms common in this sector), 
convenience of dosing schedule, and achieving an optimal concentration profile (characterized by 
zero-order release). The solution lies in the extended release and controlled release features of the 
microsphere drug delivery format. The extended release feature lies in both the choice of polymer in 
the microsphere, in this case PLGA, and a monodisperse combination of discrete microsphere size. 
The controlled release feature is expressed through the choice of large to small diameter ratio that 
was calculated both to achieve zero-order release, but also to maintain drug concentrations in the 
body at an optimal level over the course of 30 days. Achieving these product design specifications 
necessitated a precise and controllable manufacturing technology, as well as downstream processing 
methods that would preserve these characteristics and deliver them in a user-friendly format. 
Current manufacturing techniques do not allow   for the precision of size control necessary to 
achieve the specifications for these features; this project explores a new technique, cross-flow 
emulsification (XME), that can achieve these specifications. XME flow devices allow high 
production throughput of monodisperse, emulsified droplets composed of polymer and drug 
dissolved in an organic solvent. Over the course of downstream processing, the solvent is removed, 
leaving behind a hard, drug-dispersed polymer sphere.  
 
Although the basic product and process technologies were known at the outset of the 
project, rigorous optimization was necessary to generate a product that could satisfy customer needs 
and design a process that could yield the desired product at a rate acceptable to meet production 
demand. We began by developing a mathematical model, which would quantitatively predict the 
drug release kinetics of any specified depo-haloperidol sphere within the size and composition range 
under consideration. Modeling analysis gave a list of potential size and composition options that 
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would satisfy customer requirements. From here, we applied literature resources and computational 
fluid dynamics (CFD) analysis in order to tune the emulsification process in such a way that the 
process could generate particles of the specified size distribution and composition. This theoretical 
optimization then led to the detailed design of a flow channel. The architecture of the flow channel 
was considered in depth, with an eye to optimizing control over production characteristics and 
throughput. Finally, we developed a series of downstream processing operations that would prepare 
the final product for shipment to the customer.  
 
Moving forward, we turn our attention to the company under which this platform and 
product should be housed. There are several options as to where this project can grow: a large 
pharmaceutical company, a drug delivery focused firm, a generics manufacturer, or independently. 
There are also several categories of advantages and disadvantages associated with each one of these 
options: speed of regulatory approval, intellectual property in new drugs for development, access to 
capital, sales and distribution capabilities, and investment return. A large pharmaceutical firm will 
score well on all of these metrics, and is most likely the best fir for the project, especially in terms of 
growth from the development of additional drugs within the platform. It is restrictive to in the sense 
that associations with a large pharmaceutical firm will decrease the likelihood of licensing or 
collaboration with other large-cap firms in the industry. Large pharmaceutical firms like Pfizer and 
Sanofi-Aventis also contain generic subsidiaries, which would aid in supplying a steady stream of 
new drugs to develop. Large-cap firms tend to specialize over a wide spectrum of disease areas, 
because this platform is so particularly suited for applications in chronic diseases, a firm that 
specializes in areas like heart disease, diabetes, or oncology will likely be able to utilize the 
technology in more areas. Other focuses like infectious diseases, specifically in antibiotics and 
vaccines, will also benefit from the controlled release and extended release features of the drug. 
Although this paper focuses on the optimization of haloperidol within the XME platform, the 
platform is easily adaptable to other drugs. This paper elucidates solvent choices for haloperidol, a 
hydrophobic drug, but it is important to specify these choices for other types of drugs, especially 
hydrophilic drugs and biologics (proteins and antibodies). The next development steps should 
explore applications in these two areas, which will fully specify the platform and its range. Steps 
should be taken to accelerate this research, and begin to establish the XME platform’s flexibility. 
This will be a time-sensitive operation, due to the ongoing race in the pharmaceutical industry to 
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develop a ‘go-to’ drug delivery technology in-house. Each successive drug incorporated will give the 
research team increasing expertise, and be a step closer to realizing the potential of the PLGA-XME 
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